Letter by Hifumi et al Regarding Article, “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin”
To the Editor:
The article titled “Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin” by Majeed et al1 was interesting to read. The authors retrospectively reviewed bleeding reports from 5 phase III trials, comparing dabigatran with warfarin among 27 419 patients. They determined that the outcomes after major bleeding events were better in patients on dabigatran than in those on warfarin, as evidenced by a shorter stay in the intensive care unit (dabigatran, 1.6 nights; warfarin, 2.7 nights; P<0.01).
Majeed et al noted that vitamin K was administered in ≈30% patients in the warfarin group; however, …